GEP19991856B - Taxoid-Based Compositions for Injection - Google Patents

Taxoid-Based Compositions for Injection

Info

Publication number
GEP19991856B
GEP19991856B GEAP19931662A GEAP1993001662A GEP19991856B GE P19991856 B GEP19991856 B GE P19991856B GE AP19931662 A GEAP19931662 A GE AP19931662A GE AP1993001662 A GEAP1993001662 A GE AP1993001662A GE P19991856 B GEP19991856 B GE P19991856B
Authority
GE
Georgia
Prior art keywords
composition
taxoid
injection
derivatives
chosen
Prior art date
Application number
GEAP19931662A
Other languages
English (en)
Inventor
Michel Veillard
Gilles Guerin
Lanty Patrick De
Jean-Marc Bobee
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9436137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP19991856(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of GEP19991856B publication Critical patent/GEP19991856B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Detergent Compositions (AREA)
GEAP19931662A 1992-12-02 1993-11-30 Taxoid-Based Compositions for Injection GEP19991856B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9214501A FR2698543B1 (fr) 1992-12-02 1992-12-02 Nouvelles compositions à base de taxoides.

Publications (1)

Publication Number Publication Date
GEP19991856B true GEP19991856B (en) 1999-12-06

Family

ID=9436137

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19931662A GEP19991856B (en) 1992-12-02 1993-11-30 Taxoid-Based Compositions for Injection

Country Status (28)

Country Link
US (1) US5438072A (cg-RX-API-DMAC10.html)
EP (1) EP0671912B1 (cg-RX-API-DMAC10.html)
JP (1) JP3689791B2 (cg-RX-API-DMAC10.html)
KR (1) KR100330316B1 (cg-RX-API-DMAC10.html)
CN (2) CN1090170A (cg-RX-API-DMAC10.html)
AT (1) ATE190838T1 (cg-RX-API-DMAC10.html)
AU (1) AU691476B2 (cg-RX-API-DMAC10.html)
CA (1) CA2150576C (cg-RX-API-DMAC10.html)
CZ (1) CZ284080B6 (cg-RX-API-DMAC10.html)
DE (2) DE69328192D1 (cg-RX-API-DMAC10.html)
DK (1) DK0671912T3 (cg-RX-API-DMAC10.html)
ES (1) ES2145115T4 (cg-RX-API-DMAC10.html)
FI (1) FI113619B (cg-RX-API-DMAC10.html)
FR (1) FR2698543B1 (cg-RX-API-DMAC10.html)
GE (1) GEP19991856B (cg-RX-API-DMAC10.html)
GR (1) GR3032828T3 (cg-RX-API-DMAC10.html)
HU (1) HU222833B1 (cg-RX-API-DMAC10.html)
MX (1) MX9306986A (cg-RX-API-DMAC10.html)
NO (1) NO314436B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ258150A (cg-RX-API-DMAC10.html)
PL (1) PL174334B1 (cg-RX-API-DMAC10.html)
PT (1) PT671912E (cg-RX-API-DMAC10.html)
RU (1) RU2144356C1 (cg-RX-API-DMAC10.html)
SK (1) SK281558B6 (cg-RX-API-DMAC10.html)
TW (1) TW271395B (cg-RX-API-DMAC10.html)
WO (1) WO1994012171A1 (cg-RX-API-DMAC10.html)
YU (1) YU49092B (cg-RX-API-DMAC10.html)
ZA (1) ZA938936B (cg-RX-API-DMAC10.html)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
EP1652539B8 (en) 1993-07-19 2011-06-15 Angiotech Pharmaceuticals, Inc. Method of manufacturing a stent comprising an anti-angiogenic composition
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
EP0876145A4 (en) * 1995-12-21 1999-04-21 Genelabs Tech Inc TAX COMPOSITION AND PROCEDURE
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
DK0914102T3 (da) 1996-05-24 2006-01-09 Angiotech Pharm Inc Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
DE19655141C5 (de) 1996-11-08 2013-12-05 Eppendorf Ag Gradienten-Temperierblock für Laborthermostaten
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
DE69737510T2 (de) 1996-12-30 2007-12-06 Battelle Memorial Institute, Columbus Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
KR20010020342A (ko) * 1997-04-28 2001-03-15 자끄 사비나 종양치료용 맥관형성 길항제의 아데노바이러스-매개 종양내 전달방법
DE69716485T2 (de) * 1997-05-30 2003-04-10 Man Woo Han Taxol enthaltende pharmazeutische injektionslösung
CN1101677C (zh) * 1997-05-30 2003-02-19 韩万愚 含有紫杉醇的药用注射溶液
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
FR2794771B1 (fr) * 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
EP1229922B1 (en) * 1999-11-15 2007-06-06 Pharma Mar, S.A. Aplidine treatment of cancers
JP2003521545A (ja) * 2000-02-02 2003-07-15 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 改良された溶解性を有するタキサン製剤
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
EP1435908A4 (en) * 2001-09-13 2006-03-15 Korea Inst Sci & Tech Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
ES2315404T3 (es) * 2001-10-19 2009-04-01 Pharma Mar, S.A. Uso de aplidina para el tratamiento de cancer de pancreas.
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CA2484761C (en) * 2002-05-24 2010-11-09 Angiotech International Ag Compositions and methods for coating medical implants
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
PT2277551E (pt) 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
WO2005051232A2 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
BRPI0515573A (pt) * 2004-09-22 2008-07-29 Nippon Kayaku Kk copolìmero por blocos, preparação de micela e agente anticáncer contendo a mesma como o ingrediente ativo
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
EP2308467A3 (en) 2005-06-17 2011-06-22 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
KR20080106254A (ko) 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 탁산류의 고분자 결합체
AU2007252678A1 (en) 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of podophyllotoxin
WO2008041610A1 (fr) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Mélange d'un dérivé de résorcinol avec un polymère
EP2080779B1 (en) 2006-11-06 2016-05-18 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
WO2008056654A1 (fr) 2006-11-08 2008-05-15 Nippon Kayaku Kabushiki Kaisha Dérivé polymère d'un antagoniste métabolique d'acide nucléique
CA2674788A1 (en) 2007-01-08 2008-07-17 Government Of The Usa, As Represented By The Secretary, Department Of He Alth And Human Services Slco1b3 genotype
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
WO2009007992A2 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical composition produced by microprecipitation
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
EP2206502B1 (en) 2007-09-28 2018-09-12 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of steroid
CN101396354B (zh) * 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
EP2205215A2 (en) * 2007-10-01 2010-07-14 Intas Pharmaceuticals Limited Docetaxel injectable composition, being absolutely free of ethanol
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
CN102014891B (zh) 2008-03-14 2013-12-18 比奥纽默里克药物公司 增加癌症患者存活时间的化合物的组合物和使用方法
CA2717181C (en) 2008-03-14 2013-10-15 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
KR101589582B1 (ko) * 2008-03-18 2016-01-28 니폰 가야꾸 가부시끼가이샤 생리활성물질의 고분자량 결합체
AU2009225877B2 (en) 2008-03-18 2014-11-20 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
RU2428175C2 (ru) * 2008-06-02 2011-09-10 Закрытое Акционерное Общество "Биокад" Способ получения парентерального фармацевтического раствора
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
CA2754909A1 (en) 2009-03-11 2010-09-16 Ambit Biosciences Corp. Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
EP2431403B1 (en) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymer conjugate of bioactive substance having hydroxy group
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
CN102770131A (zh) 2009-10-29 2012-11-07 安万特医药股份有限公司 卡巴他赛的新颖抗肿瘤用途
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
AR079256A1 (es) 2009-12-04 2012-01-04 Genentech Inc Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
CN102947302A (zh) 2010-02-18 2013-02-27 西班牙国家癌症研究中心 三唑并[4，5-b]吡啶衍生物
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
CA2816997A1 (en) 2010-11-17 2012-05-24 Nippon Kayaku Kabushiki Kaisha Novel polymer derivative of cytidine metabolic antagonist
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
EP2694072B2 (en) 2011-04-01 2024-08-07 Genentech, Inc. Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
SG11201400681UA (en) 2011-05-19 2014-08-28 Ct Nac De Investigaciones Oncológicas Cnio Macrocyclic compounds as protein kinase inhibitors
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
PL2753355T3 (pl) 2011-09-08 2019-04-30 Benevir Biopharm Inc Onkolityczny wirus opryszczki pospolitej i jego zastosowania lecznicze
BR112014005452B1 (pt) 2011-09-11 2021-03-16 Nippon Kayaku Kabushiki Kaisha método de produção de copolímero de bloco
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US10138479B2 (en) 2012-05-24 2018-11-27 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
MX2014014831A (es) 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US10238723B2 (en) 2013-03-14 2019-03-26 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
KR20220025946A (ko) 2014-03-21 2022-03-03 애브비 인코포레이티드 항-ｅｇｆｒ 항체 및 항체 약물 접합체
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
TW202304996A (zh) 2016-06-08 2023-02-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
MX2018015272A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
US11957758B2 (en) 2017-09-07 2024-04-16 Shenzhen Salubris Pharmaceuticals Co. Ltd. Pharmaceutical composition of docetaxel conjugate and preparation method
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4507217A (en) * 1983-03-07 1985-03-26 Lipid Specialties, Inc. Magnetic compositions and magnetic memory devices prepared therefrom
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
JP2919867B2 (ja) * 1989-09-27 1999-07-19 千寿製薬株式会社 抗腫瘍剤
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Also Published As

Publication number Publication date
MX9306986A (es) 1995-01-31
ES2145115T4 (es) 2010-06-17
JPH08503689A (ja) 1996-04-23
RU2144356C1 (ru) 2000-01-20
DE69328192T4 (de) 2007-07-19
CA2150576A1 (fr) 1994-06-09
FR2698543A1 (fr) 1994-06-03
GR3032828T3 (en) 2000-06-30
NZ258150A (en) 1996-11-26
AU5566994A (en) 1994-06-22
CA2150576C (fr) 2005-06-21
ATE190838T1 (de) 2000-04-15
CN1636560A (zh) 2005-07-13
YU49092B (sh) 2003-12-31
CZ142195A3 (en) 1995-10-18
AU691476B2 (en) 1998-05-21
KR950703946A (ko) 1995-11-17
NO314436B1 (no) 2003-03-24
SK72595A3 (en) 1995-11-08
EP0671912A1 (fr) 1995-09-20
PT671912E (pt) 2000-06-30
DE69328192D1 (de) 2000-04-27
EP0671912B1 (fr) 2000-03-22
FI952680A0 (fi) 1995-06-01
US5438072A (en) 1995-08-01
JP3689791B2 (ja) 2005-08-31
DK0671912T3 (da) 2000-07-03
CN1090170A (zh) 1994-08-03
WO1994012171A1 (fr) 1994-06-09
HU222833B1 (hu) 2003-11-28
YU74593A (sh) 1996-08-13
FR2698543B1 (fr) 1994-12-30
HK1075197A1 (en) 2005-12-09
CZ284080B6 (cs) 1998-08-12
KR100330316B1 (ko) 2002-11-04
NO952151L (no) 1995-05-31
PL309197A1 (en) 1995-09-18
FI952680L (fi) 1995-06-01
ES2145115T3 (es) 2000-07-01
TW271395B (cg-RX-API-DMAC10.html) 1996-03-01
FI113619B (fi) 2004-05-31
HUT72650A (en) 1996-05-28
HU9501596D0 (en) 1995-08-28
DE69328192T2 (de) 2000-09-28
PL174334B1 (pl) 1998-07-31
NO952151D0 (no) 1995-05-31
ZA938936B (en) 1994-08-03
SK281558B6 (sk) 2001-05-10
CN1291713C (zh) 2006-12-27

Similar Documents

Publication Publication Date Title
GEP19991856B (en) Taxoid-Based Compositions for Injection
GEP20002211B (en) Taxoids, Preparation Thereof, Pharmaceutical Compositions Containing Same
GEP19991517B (en) Composition on the Basis of Taxane Derivatives and Method for its Production
CA2338358A1 (en) Compounds and compositions for delivering active agents
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
NO905572D0 (no) Fremgangsmaate for fremstilling av peptidforbindelser.
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
FI925100A0 (fi) Substituerade bifenylpyridoner
CA2336682A1 (en) Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
ES2037620A1 (es) Procedimiento para la preparacion de una composicion para la limpieza de la piel, cuero cabelludo y cabello.
DE69726457D1 (de) Pharmazeutische zusammensetzungen mit antimikrobieller wirkung
GEP20002332B (en) Cefalosporin Derivatives
ES2049690T3 (es) Derivados de taxano, su preparacion y su uso en oncologia.
CA2173147A1 (en) Anti-obesity agent
EP1219606A4 (en) ACYLOXYMETHOXYCARBONYLE PENDANT TRICYCLIC COMPOUNDS
FI844225A0 (fi) Griseolinsyraderivat och deras anvaendning.
KR950007857A (ko) 경구투여용 라파마이신 제제
BG93114A (bg) Производни на бензонафтиридин-1,8 ,методи за получаването им и състави които ги съдържат
FR2775288B1 (fr) Derives de streptogramines, leur preparation et les compositons qui les contiennent
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
IT1216104B (it) Peptidi ad attivita' farmaceutica.
BE881834A (fr) Medicaments et preparations pharmaceutiques a activite cytostatique
SE9604193L (sv) Terapeutiska och kosmetiska kompositioner, deras användning och metod för framställning därav
IL93721A0 (en) Mixed micelles compositions and their use as carriers for the parenteral application of the drugs
IT1204778B (it) Formulazioni farmaceutiche iniettabili di principi attivi ad attivita' anestetica generale